Project Description

Nexvet, a biologic therapeutics company developing a pipeline of monoclonal antibody (mAb) therapies for companion animals in pain and other therapeutic areas. Nexvet was acquired by Zoetis (NYSE:ZTS) in July 2017.

Nexvet acquired by Zoetis press release>>

If you are interested in becoming an Investor or seeking investment, then please contact us.